News Briefing channel feed

Up­dat­ed: Lon­za sets sights on ex­pan­sion, buy­ing No­var­tis fa­cil­i­ty; IQVIA leads $14 mil­lion Se­ries B fund­ing round

6 years ago

MiMedx is in trou­ble, again; Pfiz­er's Avastin biosim­i­lar wins FDA ap­proval

6 years ago

On­coSec signs on Dana-Far­ber as CAR-T part­ner; Do­va racks up an­oth­er Doptelet ap­proval

6 years ago

Ox­ford Bio­med­ica, San­ten ink gene ther­a­py pact; DayT­wo rais­es $31M in Se­ries B round

6 years ago

SQZ, Ery­tech kick off $57M cell ther­a­py part­ner­ship; Jean-Paul Kress lands new CEO gig at Mor­phoSys

6 years ago

Alex­ion wins pri­or­i­ty re­view for Ul­tomiris' aHUS in­di­ca­tion; FDA ex­pands ap­proval of Ver­tex's Symdeko

6 years ago

ICER goes af­ter No­var­tis for over­pric­ing MS drug; Val­ne­va, Glax­o­SmithK­line breaks vac­cine pact

6 years ago

NE­JM ap­points Er­ic Ru­bin to suc­ceed Jef­frey Drazen as EIC; Am­phastar pre­vails against Mo­men­ta/San­doz in years-long law­suit

6 years ago

Arc­turus ex­pands col­lab­o­ra­tion, adding $30M cash; Ku­ra shoots for $100M raise

6 years ago

Uni­ty's ear­ly longevi­ty da­ta look 'en­cour­ag­ing'; Adap­tive Biotech­nolo­gies looks to raise $200M in IPO

6 years ago

A uni­corn stalks Wall Street in search of IPO cash; CASI Phar­ma in-li­cens­es CD19 ther­a­py from Chi­na’s Ju­ven­tas

6 years ago

Chi-Med cuts su­r­u­fa­tinib PhI­II short; FDA green­lights Her­ceptin copy­cat from Am­gen, Al­ler­gan

6 years ago

Ab­b­Vie touts new da­ta for Hu­mi­ra suc­ces­sor; Gilead inks dis­cov­ery deal

6 years ago

Tech con­glom­er­ate buys Me­di­da­ta for $5.7B; Alexan­dria teams up with Co­lum­bia for sec­ond Launch­Labs; So­bi all in on ema­palum­ab

6 years ago

Nas­daq delists In­sys af­ter bank­rupt­cy fil­ing; Chi­na's Zai Lab li­cens­es sol­id tu­mor drug from De­ci­phera

6 years ago

FDA sends No­vaVax back to the clin­ic; Stoke Ther­a­peu­tics sets terms for up­sized $101M IPO

6 years ago

Ot­su­ka scores PhI­II win for an­oth­er As­tex drug; GSK ex­pands Nu­cala use in asth­ma

6 years ago

Vivek Ra­maswamy re­cruits Eli Lil­ly R&D vet Salz­mann as new CEO; Ax­o­vant drops col­lab­o­ra­tion

6 years ago

Deer­field strikes up new deal with Co­lum­bia Uni­ver­si­ty; Ovid CEO Je­re­my Levin joins BIO as new board chair

6 years ago

Cel­gene/Ac­celeron win speedy FDA re­view for lus­pa­ter­cept in be­ta tha­lassemia; Ko­re­an in­vestor out to shake up Au­rini­a's board

6 years ago

Eye­Gate surges on FDA nod to start piv­otal study; Alde­vron to build gene ther­a­py man­u­fac­tur­ing cam­pus in Far­go, N.D.

6 years ago

Novo's in­vest­ment arm in­jects $67.5M in Ox­ford Bio­med­ica; Aba­cus Med­i­cine de­lays IPO plans

6 years ago

No­var­tis backs $30M round for can­cer biotech; Bay­er drug makes a ‘break­through’ at FDA

6 years ago

Mallinck­rodt up­dates spin-off plans; FDA ex­pands Vray­lar ap­proval for Al­ler­gan; Ju­ve­nes­cence spawns Sou­vien Ther­a­peu­tics

6 years ago
First page Previous page 48495051525354 Next page Last page
A service from the Financial Times